MRKR Marker Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRKR

Price (delayed)

$4.2

Market cap

$37.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.94

Enterprise value

$22.28M

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy ...

Highlights
The EPS has soared by 74% year-on-year and by 12% since the previous quarter
MRKR's net income has surged by 72% year-on-year and by 11% since the previous quarter
Marker Therapeutics's quick ratio has soared by 188% YoY but it has decreased by 17% from the previous quarter
MRKR's revenue is down by 49% since the previous quarter and by 6% year-on-year
Marker Therapeutics's gross profit has decreased by 49% QoQ and by 6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://markertherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of MRKR
Market
Shares outstanding
8.9M
Market cap
$37.39M
Enterprise value
$22.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.66
Price to sales (P/S)
11.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.73
Earnings
Revenue
$3.31M
EBIT
-$8.23M
EBITDA
-$8.23M
Free cash flow
-$16.44M
Per share
EPS
-$0.94
Free cash flow per share
-$1.87
Book value per share
$1.58
Revenue per share
$0.38
TBVPS
$1.94
Balance sheet
Total assets
$17.13M
Total liabilities
$3.07M
Debt
$0
Equity
$14.05M
Working capital
$14.05M
Liquidity
Debt to equity
0
Current ratio
5.57
Quick ratio
5.25
Net debt/EBITDA
1.84
Margins
EBITDA margin
-248.7%
Gross margin
100%
Net margin
-248.8%
Operating margin
-440.4%
Efficiency
Return on assets
-38.1%
Return on equity
-50.1%
Return on invested capital
-143.7%
Return on capital employed
-58.6%
Return on sales
-248.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRKR stock price

How has the Marker Therapeutics stock price performed over time
Intraday
2.44%
1 week
-3.89%
1 month
-3.67%
1 year
271.68%
YTD
-23.64%
QTD
-2.33%

Financial performance

How have Marker Therapeutics's revenue and profit performed over time
Revenue
$3.31M
Gross profit
$3.31M
Operating income
-$14.58M
Net income
-$8.24M
Gross margin
100%
Net margin
-248.8%
MRKR's operating margin has dropped by 86% since the previous quarter but it is up by 22% year-on-year
The company's net margin has shrunk by 74% QoQ but it has surged by 71% YoY
MRKR's net income has surged by 72% year-on-year and by 11% since the previous quarter
MRKR's revenue is down by 49% since the previous quarter and by 6% year-on-year

Growth

What is Marker Therapeutics's growth rate over time

Valuation

What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
2.66
P/S
11.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.73
The EPS has soared by 74% year-on-year and by 12% since the previous quarter
The P/B is 40% above the last 4 quarters average of 1.9 and 6% above the 5-year quarterly average of 2.5
Marker Therapeutics's equity has decreased by 28% YoY and by 16% from the previous quarter
MRKR's P/S is 77% above its last 4 quarters average of 6.3
MRKR's revenue is down by 49% since the previous quarter and by 6% year-on-year

Efficiency

How efficient is Marker Therapeutics business performance
The ROS has dropped by 74% since the previous quarter but it has soared by 71% year-on-year
The ROE has soared by 56% year-on-year and by 4% since the previous quarter
The company's return on invested capital has shrunk by 50% QoQ and by 6% YoY
The ROA has grown by 42% YoY but it has contracted by 6% from the previous quarter

Dividends

What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRKR.

Financial health

How did Marker Therapeutics financials performed over time
Marker Therapeutics's quick ratio has soared by 188% YoY but it has decreased by 17% from the previous quarter
The current ratio has soared by 160% YoY but it has contracted by 21% from the previous quarter
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has decreased by 28% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.